Name of opportunity: 👀
Novo Nordisk A/S
Incredible in early trials: 💊
Novo Nordisk is the company behind the amazingly popular weight loss drug behind Wegovy that mimics the effects of natural hormones to make patients feel less hungry, digest more slowly, and ultimately lose weight.
Now, the pharma company has a new drug in human trials, amycretin. Unlike its predecessors, amycretin is taken in pill form - and trial participants at the highest dose lost up to 13.1% of their body weight over 12 weeks.
Head of Development Martin Holst Lange said earlier this year that amycretin will likely be available before 2030.
How hot is this investment opportunity? 🔥🔥🔥
Analysts predict the price of Novo Nordisk A/S will increase from $131.97 to $155.43 in the next 12 months. If you invested $1000, you might profit $182.51.
The positive news about the development of amycretin is one reason investors and analysts are currently feeling good about Novo Nordisk. According to recent information from the trial, the drug is "safe and well-tolerated" although at this stage of development it does have a risk of "mild to moderate" side effects, mostly nausea and vomiting.
Another potential reason for the stock's current outlook is that liraglutide, another drug made by the company for weight management, has been found in a study released today to be suitable for children as young as six, helping them to lose weight safely. This would open up a new market for Novo Nordisk.
One of the world’s most famous pharma brands: 🩺
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. Novo Nordisk’s history dates back to the 1920s when the Danish company Nordisk Insulinlaboratorium started producing insulin commercially.
Investors who are interested in Novo’s amycretin and this industry should also take a look at Novo Nordisk’s competitors Eli Lilly, Viking Therapeutics, AstraZeneca, Pfizer and Roche, all of which are currently developing weight loss pills.
Which neme?: 🔍
‘Top Biotech Stocks’, ‘Pharma’ and ‘FutureTech: World Changing Ideas’
Download Nemo to check out Novo Nordisk
